FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.

BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been ac...